drugset / Trial / NCT05179525
Comparative Bioavailability of Risperidone.
NaSequentialOpen-labelTreatment
Summary
This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
Timeline
- Start
- 2021-03-09
- Primary completion
- 2021-09-17
- Completion
- 2021-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 4 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 100 mg | Intramuscular |